Dinesh Atwal1, Krishna P Joshi2, Rahul Ravilla3, Fade Mahmoud4. 1. Resident Internist at the University of Arkansas for Medical Sciences in Little Rock. datwal@uams.edu. 2. Resident Internist at the University of Arkansas for Medical Sciences in Little Rock. kpjoshi@uams.edu. 3. Fellow Physician in the Department of Hematology and Oncology at the University of Arkansas for Medical Sciences in Little Rock. rravilla@uams.edu. 4. Assistant Professor of Medicine in the Department of Hematology and Oncology at the University of Arkansas for Medical Sciences in Little Rock. fmahmoud@uams.edu.
Abstract
INTRODUCTION: Programmed death receptor-1 blockade with pembrolizumab is approved by the US Food and Drug Administration to treat patients with metastatic melanoma. Activating T cells to fight cancer may cause immune-mediated adverse events. Pembrolizumab-induced pancytopenia has not been previously reported in the medical literature, to our knowledge. CASE PRESENTATION: A 52-year-old Caucasian woman with a diagnosis of metastatic melanoma of the rectum experienced multiple adverse events along her course of therapy with pembrolizumab, ranging from colitis, hepatitis, gastritis, and vitiligo after the fifth cycle of pembrolizumab; to knee synovitis after the 14th cycle; and to severe pancytopenia after the 18th cycle of pembrolizumab. Severe pancytopenia improved after high-dose corticosteroids and a 5-day course of intravenous immunoglobulin therapy. DISCUSSION: In our case, pembrolizumab-induced Grade 4 pancytopenia resolved via a combination of corticosteroids and intravenous immunoglobulins. Pancytopenia reached a nadir in 10 weeks, and it took 16 weeks for meaningful recovery.
INTRODUCTION: Programmed death receptor-1 blockade with pembrolizumab is approved by the US Food and Drug Administration to treat patients with metastatic melanoma. Activating T cells to fight cancer may cause immune-mediated adverse events. Pembrolizumab-induced pancytopenia has not been previously reported in the medical literature, to our knowledge. CASE PRESENTATION: A 52-year-old Caucasian woman with a diagnosis of metastatic melanoma of the rectum experienced multiple adverse events along her course of therapy with pembrolizumab, ranging from colitis, hepatitis, gastritis, and vitiligo after the fifth cycle of pembrolizumab; to knee synovitis after the 14th cycle; and to severe pancytopenia after the 18th cycle of pembrolizumab. Severe pancytopenia improved after high-dose corticosteroids and a 5-day course of intravenous immunoglobulin therapy. DISCUSSION: In our case, pembrolizumab-induced Grade 4 pancytopenia resolved via a combination of corticosteroids and intravenous immunoglobulins. Pancytopenia reached a nadir in 10 weeks, and it took 16 weeks for meaningful recovery.
Authors: Jeffrey S Weber; Sandra P D'Angelo; David Minor; F Stephen Hodi; Ralf Gutzmer; Bart Neyns; Christoph Hoeller; Nikhil I Khushalani; Wilson H Miller; Christopher D Lao; Gerald P Linette; Luc Thomas; Paul Lorigan; Kenneth F Grossmann; Jessica C Hassel; Michele Maio; Mario Sznol; Paolo A Ascierto; Peter Mohr; Bartosz Chmielowski; Alan Bryce; Inge M Svane; Jean-Jacques Grob; Angela M Krackhardt; Christine Horak; Alexandre Lambert; Arvin S Yang; James Larkin Journal: Lancet Oncol Date: 2015-03-18 Impact factor: 41.316
Authors: Benjamin Y Kong; Kenneth P Micklethwaite; Sanjay Swaminathan; Richard F Kefford; Matteo S Carlino Journal: Melanoma Res Date: 2016-04 Impact factor: 3.599
Authors: Padmanee Sharma; Margaret K Callahan; Petri Bono; Joseph Kim; Pavlina Spiliopoulou; Emiliano Calvo; Rathi N Pillai; Patrick A Ott; Filippo de Braud; Michael Morse; Dung T Le; Dirk Jaeger; Emily Chan; Chris Harbison; Chen-Sheng Lin; Marina Tschaika; Alex Azrilevich; Jonathan E Rosenberg Journal: Lancet Oncol Date: 2016-10-09 Impact factor: 41.316
Authors: Lisa Zimmer; Julia Vaubel; Peter Mohr; Axel Hauschild; Jochen Utikal; Jan Simon; Claus Garbe; Rudolf Herbst; Alexander Enk; Eckhart Kämpgen; Elisabeth Livingstone; Leonie Bluhm; Rainer Rompel; Klaus G Griewank; Michael Fluck; Bastian Schilling; Dirk Schadendorf Journal: PLoS One Date: 2015-03-11 Impact factor: 3.240
Authors: Nabil E Omar; Kareem A El-Fass; Abdelrahman I Abushouk; Noha Elbaghdady; Abd Elmonem M Barakat; Ahmed E Noreldin; Dina Johar; Mohamed Yassin; Anas Hamad; Shereen Elazzazy; Said Dermime Journal: Front Immunol Date: 2020-10-21 Impact factor: 7.561